Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: Results from the stop 1 and stop 2 studies

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 675-680

  Taylor, Stephen ^a,b   Jayasuriya, Ashini ^a,c   Fisher, Martin ^d   Allan, Sris ^e   Wilkins, Ed ^f   Gilleran, Gerry ^a   Heald, Lisa ^d   Fidler, Sarah ^g   Owen, Andrew ^h   Back, David ^h   Smit, Erasmus ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d UK   (United Kingdom)

^e Hospital of Coventry and Warwickshire   (United Kingdom)

^f NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Efavirenz; HIV; Lopinavir ritonavir monotherapy; Pharmacokinetics; Stopping therapy

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HETEROZYGOSITY; HUMAN; MALE; MONOTHERAPY; PHARMACOLOGY; SEX; TABLET; TREATMENT DURATION; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV; HIV INFECTIONS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; PLASMA; RITONAVIR; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84856971556     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr491     Document Type: Article

References (27)

1. Taylor S, Boffito M, Khoo S et al. Stopping antiretroviral therapy. AIDS 2007; 21: 1673-82.
2. Fox Z, Phillips A, Cohen C et al. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 2008; 22: 2279-89.
3. Halvas EK, Wiegand A, Boltz VF et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 2010; 201: 672-80.
4. Palmer S, Boltz V, Maldarelli F et al. Selection and persistence of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 2006; 20: 701-10.
5. Darwich L, Esteve A, Ruiz L et al. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption. Antivir Ther 2008; 13: 945-51.
6. Cressey TR, Jourdain G, Lallemant MJ et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2005; 38: 283-8.
7. Ribaudo HJ, Haas DW, Tierney C et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42: 401-7.
8. Mackie NE, Fidler S, Tamm N et al. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med 2004; 5: 180-4.
9. electronic Medicines Compendium. SPC: Sustiva 600 mg Film-coated Tablets. http://www.medicines.org.uk/EMC/medicine/11284/SPC/Sustiva+600+mg+Film-Coated+Tablets/ (25 November 2010, date last accessed).
10. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
11. Wyen C, Hendra H, Vogel M et al. Impact of CYP2B6 983T.C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61: 914-8.
12. Centers for Disease Control and Prevention. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents, 10 Jan 2011. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. (20 September 2011, date last accessed).
13. The European AIDS Clinical Society. Clinical Management and Treatment of HIV Infected Adults in Europe, Version 5-4. http://www.europeanaidsclinicalsociety.org/ (20 September 2011, date last accessed).
14. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach: 2010 Revision. http://www.who.int/hiv/pub/arv/adult2010/en/index.html (20 September 2011, date last accessed).
15. Almond LM, Hoggard PG, Edirisinghe D et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 2005; 56: 738-44.
16. Marzolini C, Telenti A, Decosterd LA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-5.
17. D'Avolio A, Sciandra M, Siccardi M et al. A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. J Chromatogr Sci 2008; 46: 524-8.
18. Else L, Watson V, Tjia J et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1455-65.
19. Gatanaga H, Hayashida T, Tsuchiya K et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45: 1230-7.
20. Rotger M, Saumoy M, Zhang K et al. Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet Genomics 2007; 17: 885-90.
21. Wang J, Sonnerborg A, Rane A et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006; 16: 191-8.
22. Taylor S, Allen S, Fidler S et al. Stop Study: after discontinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer. In: Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004. Abstract 131.
23. Ananworanich J, Nuesch R, Le BM et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17: F33-7.
24. Sadiq ST, Fredericks S, Khoo SH et al. Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. AIDS 2005; 19: 1716-7.
25. Fidler S, Oxenius A, Brady M et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002; 16: 2049-54.
26. Tommasi C, Nicastri E, Corpolongo A et al. Stopping antiretroviral therapy: role for therapeutic drug monitoring. AIDS 2008; 22: 315-6.
27. Anderson PL. Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs. Curr Opin HIV AIDS 2008; 3: 258-65.